Previous Article | Next Article ![]()
J. Virol., 11 1996, 7498-7509, Vol 70, No. 11
N Mittereder, KL March and BC Trapnell
Development of adenovirus vectors as potential therapeutic agents for
multiple applications of in vivo human gene therapy has resulted in
numerous preclinical and clinical studies. However, lack of standardization
of the methods for quantifying the physical concentration and functionally
active fraction of virions in these studies has often made comparison
between various studies difficult or impossible. This study was therefore
carried out to define the variables for quantification of the concentration
of adenovirus vectors. The methods for evaluation of total virion
concentration included electron microscopy and optical absorbance. The
methods for evaluation of the concentration of functional virions included
detection of gene transfer (transgene transfer and expression) and the
plaque assay on 293 cells. Enumeration of total virion concentration by
optical absorbance was found to be a precise procedure, but accuracy was
dependent on physical disruption of the virion to eliminate artifacts from
light scattering and also on a correct value for the extinction
coefficient. Both biological assays for enumerating functional virions were
highly dependent on the assay conditions and in particular the time of
virion adsorption and adsorption volume. Under optimal conditions, the
bioactivity of the vector, defined as the fraction of total virions which
leads to detected target cell infection, was determined to be 0.10 in the
plaque assay and 0.29 in the gene transfer assay. This difference is most
likely due to the fact that detection by gene transfer requires only
measurement of levels of transgene expression in the infected cell whereas
plaque formation is dependent on a series of biological events of much
greater complexity. These results show that the exact conditions for
determination of infectious virion concentration and bioactivity of
recombinant adenovirus vectors are critical and must be standardized for
comparability. These observations may be very useful in comparison of data
from different preclinical and clinical studies and may also have important
implications for how adenovirus vectors can optimally be used in human gene
therapy.
Copyright © 1996, American Society for Microbiology
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
Department of Virology, Genetic Therapy, Inc., Gaithersburg, Maryland 20878, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|